Rivaroxaban Teva 20 mg apvalkotās tabletes Lettonia - lettone - Zāļu valsts aģentūra

rivaroxaban teva 20 mg apvalkotās tabletes

teva gmbh, germany - rivaroksabans - apvalkotā tablete - 20 mg

Apixaban Viatris 2,5 mg apvalkotās tabletes Lettonia - lettone - Zāļu valsts aģentūra

apixaban viatris 2,5 mg apvalkotās tabletes

viatris limited, ireland - apiksabāns - apvalkotā tablete - 2,5 mg

Apixaban Viatris 5 mg apvalkotās tabletes Lettonia - lettone - Zāļu valsts aģentūra

apixaban viatris 5 mg apvalkotās tabletes

viatris limited, ireland - apiksabāns - apvalkotā tablete - 5 mg

Fraxiparina 0,3 ml šķīdums injekcijām Lettonia - lettone - Zāļu valsts aģentūra

fraxiparina 0,3 ml šķīdums injekcijām

aspen pharma trading ltd., ireland - nadroparīna kalcija sāls - Šķīdums injekcijām - 2850 sv axa/0,3 ml

Fraxiparina 0,4 ml šķīdums injekcijām Lettonia - lettone - Zāļu valsts aģentūra

fraxiparina 0,4 ml šķīdums injekcijām

aspen pharma trading ltd., ireland - nadroparīna kalcija sāls - Šķīdums injekcijām - 3800 sv axa/0,4 ml

Fraxiparina 0,6 ml šķīdums injekcijām Lettonia - lettone - Zāļu valsts aģentūra

fraxiparina 0,6 ml šķīdums injekcijām

aspen pharma trading ltd., ireland - nadroparīna kalcija sāls - Šķīdums injekcijām - 5700 sv axa/0,6 ml

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Unione Europea - lettone - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiskie līdzekļi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Aboxoma 2,5 mg apvalkotās tabletes Lettonia - lettone - Zāļu valsts aģentūra

aboxoma 2,5 mg apvalkotās tabletes

krka, d.d., novo mesto, slovenia - apiksabāns - apvalkotā tablete - 2,5 mg

Aboxoma 5 mg apvalkotās tabletes Lettonia - lettone - Zāļu valsts aģentūra

aboxoma 5 mg apvalkotās tabletes

krka, d.d., novo mesto, slovenia - apiksabāns - apvalkotā tablete - 5 mg

Fraxiparine 2850 SV (anti-Xa)/0,3 ml šķīdums injekcijām Lettonia - lettone - Zāļu valsts aģentūra

fraxiparine 2850 sv (anti-xa)/0,3 ml šķīdums injekcijām

mylan epd bvba/sprl, belgium - nadroparīna kalcija sāls - Šķīdums injekcijām pilnšļircē - 2850 sv axa/0,3 ml